share_log

Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 4.8%

Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 4.8%

Reneo Pharmicals（納斯達克股票代碼：RPHM）交易上漲4.8％
Defense World ·  2022/12/27 02:02

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating) shares shot up 4.8% during mid-day trading on Monday . The stock traded as high as $2.21 and last traded at $2.19. 10 shares traded hands during trading, a decline of 100% from the average session volume of 52,943 shares. The stock had previously closed at $2.09.

Reneo Pharmicals, Inc.（納斯達克股票代碼：RPHM — 獲取評級）股價在週一午盤交易中飆升了4.8％。該股交易價格高達2.21美元，最後一次交易價格爲2.19美元。交易期間有10股交易，較平均交易量52,943股下降了100％。該股此前收於2.09美元。

Wall Street Analyst Weigh In

華爾街分析師權衡一下

Separately, HC Wainwright reiterated a "buy" rating and issued a $31.00 price objective on shares of Reneo Pharmaceuticals in a research report on Monday, September 19th.

另外，HC Wainwright在9月19日星期一的一份研究報告中重申了 “買入” 評級，並對Reneo Pharmicals的股票發佈了31.00美元的目標股價。

Get
獲取
Reneo Pharmaceuticals
Reneo 製藥
alerts:
警報：

Reneo Pharmaceuticals Stock Performance

Reneo 製藥股票表現

The business's 50 day moving average price is $2.56 and its 200-day moving average price is $2.91. The company has a market cap of $53.72 million, a price-to-earnings ratio of -1.10 and a beta of 0.64.

該公司的50天移動平均價格爲2.56美元，其200天移動平均線價格爲2.91美元。該公司的市值爲5,372萬美元，市盈率爲-1.10，beta值爲0.64。

Institutional Inflows and Outflows

機構流入和流出

Several hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Reneo Pharmaceuticals during the second quarter valued at approximately $457,000. Barclays PLC boosted its stake in Reneo Pharmaceuticals by 33.3% in the 3rd quarter. Barclays PLC now owns 71,930 shares of the company's stock valued at $241,000 after buying an additional 17,984 shares in the last quarter. Northern Trust Corp grew its position in Reneo Pharmaceuticals by 7.7% in the first quarter. Northern Trust Corp now owns 68,424 shares of the company's stock valued at $201,000 after acquiring an additional 4,877 shares during the period. Millennium Management LLC acquired a new position in Reneo Pharmaceuticals during the second quarter worth $158,000. Finally, UBS Group AG lifted its holdings in shares of Reneo Pharmaceuticals by 5,012.5% during the second quarter. UBS Group AG now owns 54,550 shares of the company's stock valued at $145,000 after acquiring an additional 53,483 shares during the period. Institutional investors and hedge funds own 75.61% of the company's stock.
幾家對沖基金最近增加了或減少了在該業務中的股份。Citadel Advisors LLC在第二季度收購了Reneo Pharmicals的新股份，價值約爲45.7萬美元。巴克萊集團在第三季度將其在Reneo Pharmicals的股份增加了33.3％。巴克萊集團在上個季度又購買了17,984股股票後，現在擁有該公司71,930股股票，價值24.1萬美元。北方信託公司在第一季度將其在Reneo Pharmicals的地位增長了7.7％。Northern Trust Corp在此期間又收購了4,877股股票後，現在擁有該公司68,424股股票，價值201,000美元。千禧管理有限責任公司在第二季度收購了Reneo Pharmicals的新職位，價值15.8萬美元。最後，瑞銀集團股份公司在第二季度將其持有的Reneo Pharmicals的股票增加了5,012.5％。瑞銀集團股份公司在此期間又收購了53,483股股票後，現在擁有該公司54,550股股票，價值14.5萬美元。機構投資者和對沖基金擁有該公司75.61％的股票。

About Reneo Pharmaceuticals

關於 Reneo 製藥

(Get Rating)

（獲取評分）

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.

Reneo Pharmicals, Inc是一家處於臨床階段的製藥公司，專注於罕見遺傳線粒體疾病患者的療法的開發和商業化。其主要候選產品是 REN001，這是一種強效的選擇性過氧化物酶體增殖物激活受體 delta 的激動劑，正在臨床開發用於遺傳線粒體疾病，包括原發性線粒體肌病和長鏈脂肪酸氧化障礙。

See Also

另見

  • Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
  • Three Healthcare Penny Stocks to Watch In The New Year
  • Southwest Airlines Stock, There is a Lot to Love
  • MarketBeat: Week in Review 12/19 – 12/23
  • These Steelmakers Deserve A Place On Your 2023 Watch List
  • Inflation Cools, Where Does The S&P 500 Go Now
  • 免費獲取 StockNews.com 關於 Reneo Pharmicals（RPHM）的研究報告的副本
  • 新年值得關注的三隻醫療保健細價股
  • 西南航空股票，有很多值得愛的地方
  • MarketBeat：本週回顧 12 月 19 日 — 12 月 23 日
  • 這些鋼鐵製造商值得在你的 2023 年觀察名單上佔有一席之地
  • 通貨膨脹降溫，標準普爾500指數現在走向何方

Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收Reneo Pharmicals每日的新聞和收視率 -在下面輸入您的電子郵件地址，通過Marketbeat.com的免費每日電子郵件時事通訊接收Reneo Pharmicals及相關公司最新新聞和分析師評級的簡明每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論